
Opinion|Videos|September 19, 2024
Sequencing Axatilimab and Safety
Panelists discuss where and when sequencing axatilimab becomes appropriate within the clinical setting, as well as safety precautions associated with the drug.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
3
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5
















